Page 34 - Recursion Pharmaceuticals News Today

Nvidia's investment in Recursion caused its stock price to jump dramatically on Tuesday.

Nvidia just invested millions into Recursion Pharmaceuticals, bolstering AI integration in biotech but also presenting risks for RXRX stock.

Harpoon Therapeutics (NASDAQ:HARP – Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Volatility and Risk Harpoon Therapeutics has a beta of […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) COO Tina Marriott Larson sold 3,000 shares of the stock in a transaction that occurred on Thursday, June 29th. The stock was sold at an average price of $7.49, for a total transaction of $22,470.00. Following the completion of the transaction, the chief operating officer now owns 424,160 […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) Director Blake Borgeson sold 8,885 shares of the company’s stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $7.39, for a total transaction of $65,660.15. Following the transaction, the director now directly owns 7,528,989 shares of the company’s stock, valued […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) Director Blake Borgeson sold 8,885 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $7.39, for a total transaction of $65,660.15. Following the completion of the sale, the director now owns 7,528,989 shares of […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s share price was down 4.8% during mid-day trading on Thursday following insider selling activity. The stock traded as low as $9.05 and last traded at $9.39. Approximately 270,739 shares changed hands during trading, a decline of 82% from the average daily volume of 1,493,078 shares. The stock had […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 15,485 shares of the firm’s stock in a transaction on Tuesday, June 13th. The stock was sold at an average price of $9.98, for a total transaction of $154,540.30. Following the completion of the sale, the director now owns 7,525,262 shares in the company, […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $8.63, but opened at $9.00. Recursion Pharmaceuticals shares last traded at $9.18, with a volume of 293,828 shares changing hands. Wall Street Analysts Forecast Growth RXRX has been the topic of a […]

Schroder Investment Management Group increased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 47.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 159,964 shares of the company’s stock after acquiring an additional 51,119 shares during the period. Schroder Investment Management Group’s holdings in Recursion Pharmaceuticals were worth $1,233,000 at the […]